Antenatal testing for cystic fibrosis in Cuba, 1988-2011
Teresa Collazo PhDI; Ixchel LópezII; Yulia Clark MSIII; Yaixa Piloto MSIV; Laura GonzálezV; Manuel GómezVI; Marileivis GarcíaVII; Lidice ReyesVIII; Fidel Rodríguez MDIX
IBiochemist. Senior researcher, National Medical Genetics Center (CNGM), Havana, Cuba. (Corresponding author: email@example.com)
IIBiologist. Research candidate, CNGM, Havana, Cuba
IIIBiochemist with a master's degree in molecular biology. Adjunct researcher, CNGM, Havana, Cuba
IVBiochemist with a master's degree in medical genetics. Adjunct researcher, CNGM, Havana, Cuba
VChemist. Research candidate, CNGM, Havana, Cuba
VIChemist, CNGM, Havana, Cuba
VIIChemist, CNGM, Havana, Cuba
VIIIChemist, CNGM, Havana, Cuba
IXPulmonologist, Calixto García University Hospital, Havana, Cuba
INTRODUCTION: Cystic fibrosis is a multisystem autosomal recessive disease with wide variability in clinical severity. It is incurable and characterized by elevated and premature mortality, as well as poor quality of life. Its frequency, lethality and devastating impact on both the physical and psychological wellbeing of patients and their families, make it a serious health problem. Its frequency in Cuba is 1 in 9862 live births, where marked molecular heterogeneity of the CFTR gene makes molecular diagnosis difficult. Six mutations have been identified that together enable molecular characterization of only 55.5% of cystic fibrosis chromosomes. This paper presents national results of antenatal diagnostic testing, using direct and indirect methods, for detection of cystic fibrosis.
OBJECTIVE: Characterize the Cuban public health system's experience with antenatal molecular testing for cystic fibrosis from 1988 through 2011.
METHODS: A retrospective descriptive study was conducted with results of antenatal diagnostic testing of amniotic fluid, performed nationwide from 1988 through 2011, for 108 fetuses of couples with some risk of having children affected by cystic fibrosis, who requested testing. Polymerase chain reaction detected mutations p.F508del, p.G542X, p.R1162X, p.R334W, p.R553X and c.3120+1G>A, and markers XV2C and KM19. Data were analyzed using absolute frequencies and percentages, and presented in tables.
RESULTS: For 93 cases (86.1%), testing for cystic fibrosis was done using direct analysis of mutations p.F508del, p.G542X, p.R1162X, p.R334W, p.R553X and c.3120+1G>A; five cases (4.6%) were tested indirectly using markers XV2C/Taq I and KM19/Pst I; and 10 (9.3%) were tested using a combination of the two methods. A total of 72 diagnoses (66.7% of studies done) were concluded, of which there were 20 healthy fetuses, 16 affected, 27 carrier, and 9 who were either healthy or carriers of an unknown mutation.
CONCLUSIONS: Direct or indirect molecular study was successfully used in over half of antenatal tests requested by couples throughout Cuba at risk of having children affected by cystic fibrosis, which is of great social value because of CF's burden on affected persons and their families.
Keywords: Cystic fibrosis, CFTR protein, molecular markers, antenatal diagnosis, antenatal screening, Cuba
Cystic fibrosis (CF) is a multisystem disease affecting growth, respiratory function and digestion (mainly involving the lungs, intestines, sweat ducts and vas deferens). It presents wide variability in clinical severity and is incurable. CF is characterized by elevated and premature mortality, as well as poor quality of life. Symptoms vary, depending on mutation type, patient age, degree to which specific organs are affected, prior therapy and type of infection associated. The neonatal period is characterized by poor weight gain and intestinal obstruction. Other symptoms appear later in childhood and early adulthood, including growth retardation, lung disease and increasing problems related to nutrient malabsorption in the gut.[3,4]
CF is a health problem worldwide, constituting the most frequent autosomal recessive disease in European-descended populations.[5,6] It also presents a health problem in Cuba, where, according to recent data from the National Cystic Fibrosis Commission, the disease occurs in 1 in 9862 live births. From 2001 through 2008, a total of 30 CF patients died, 33% of them aged <1 year.
The gene responsible for CF was identified in 1989 and named the CF transmembrane conductance regulator gene (CFTR); the principal mutation, p.F508del, was also identified. Since then, over 1900 mutations have been described. Studies of various population groups have found considerable differences in frequencies of the most common mutations. Mutation p.F508del has been detected in 30%-90% of patients, depending on their ethnic origin.[11-13]
Given the ethnic origins of the Cuban population, research began by detecting the most frequent mutations found in Spain's population (p.F508del, p.G542X, p.R1162X, p.R334W and p.R553X) and the one most frequent in African populations (c.3120+1G>A). Only 55.5% of chromosomes with CF genes were identified; thus, Cuba's population can be considered highly heterogeneous, making molecular diagnosis difficult.
Direct diagnosis is the ideal method for detecting the genetic defect. This is quite feasible in populations without major molecular heterogeneity and with few mutations, but in very heterogeneous populations such as Cuba's, it cannot be used in most couples potentially affected by CF. Indirect diagnosis is then indicated, using molecular markers such as XV2C and KM19 polymorphisms, and combinations of both methods-direct mutation detection and molecular marker analysis-to increase the chances of conclusive antenatal diagnosis.
Given CF's severity, antenatal testing is important for at-risk couples, indicating to them whether their child may be healthy, affected or a carrier. This knowledge also facilitates tailored genetic counseling, as well as early treatment for better prognosis and quality of life for the baby, should the couple decide to continue with the pregnancy.
In Cuba's public health system, such testing became available in the 1980s, first by enzyme analysis in amniotic fluid; later by indirect analysis, using restriction fragment length polymorphisms (RFLPs) as molecular markers; and finally, following cloning of the CFTR gene, by direct analysis of the gene's mutations. The country began antenatal molecular diagnosis in 1987 at the laboratory of the National Medical Genetics Center (CNGM, the Spanish acronym). Antenatal testing in Cuba is performed for all couples requesting it, whether carriers, CF patients, or couples for whom the disease is suspected on ultrasound. Cases are seen at provincial medical genetics centers and samples are sent to CNGM.
The objective of our research was to characterize the Cuban public health system's experience with antenatal molecular testing for cystic fibrosis from 1988 through 2011.
A retrospective descriptive study was done using CNGM laboratory data, results from testing on amniotic fluid from 108 fetuses of couples with some risk of having children affected by CF, referred from all parts of Cuba from 1988 through 2011.
Data collection Variables are described in Table 1.
CNGM laboratory methods Amniotic fluid contaminated with maternal blood is discarded to prevent equivocal results. DNA is extracted by the salting-out method using 20 mL of amniotic fluid, as described by Miller. Once DNA samples are obtained, they are coded and stored until use.
Markers XV2C/Taq I and KM19/Pst I are used for indirect analysis. They are detected by PCR and enzyme digestion by the respective restriction enzymes Taq I and Pst I, according to protocols described by Casals. The process uses a thermal cycler (MJ Research, USA) and samples are analyzed by 2% agarose gel electrophoresis. Alleles are segregated for each marker in each case. When a child enters the program, parents are also tested for the markers of interest. Families are informative when both parents are heterozygous for the markers and the affected person is homozygous; semi-informative when one parent is heterozygous for the marker; and non-informative when both parents are homozygous for the marker, or parents and patient are heterozygous.
All sampes are tested for mutations p.F508del, p.G542X, p.R1162X, p.R334W, p.R553X and c.3120+1G>A.
Three mutations-p.F508del, p.G542X and p.R1162X(11)-are detected using the amplification refractory mutation system (ARMS). The other three-p.R334W, p.R553X and c.3120+1G>A- are directly detected by enzyme digestion of the corresponding PCR product, amplified in a thermal cycler (MJ Research, USA) and fragments observed on 2% agarose gel stained with ethidium bromide.
Analysis Data were analyzed using summary measures for qualitative variables, absolute frequencies and percentages.
Ethical considerations The study was approved by the CNGM ethics committee and endorsed by the National Cystic Fibrosis Commission. Couples included had received genetic counseling and given written informed consent for antenatal molecular testing, including permission to use their data for future research. Patient privacy was protected throughout the analysis process.
Data were available for antenatal genetic testing conducted from 1988 through 2011, for 108 pregnancies of gestational age ranging from 16-20 weeks. Testing was repeated for four couples; one couple had a twin pregnancy.
Of the 108 antenatal tests carried out, 91 were for couples with a previous child affected by CF, the child having died in 43 (39.8%) of these cases; and 4 (3.7%) were carrier parents with a new partner. Fifteen couples (13.9%) were referred because ultrasound had detected echogenic bowel. In two couples (1.8%), one of the partners was a CF patient.
Case distribution for the 108 couples by antenatal diagnostic method was as follows: 93 (86.1%) diagnoses were made by direct analysis looking for mutations p.F508del, p.G542X, p.R1162X, p.R334W, p.R553X and c.3120+1G>A; 5 (4.6%) were diagnosed by indirect method using markers XV2C/Taq I and KM19/Pst I; and 10 (9.3%) combined the two methods.
Of the 93 antenatal tests searching for mutations p.F508del, p.G542X, p.R1162X, p.R334W, p.R553X and c.3120+1G>A, diagnosis was confirmed in 61 (65.6%) cases. Of these, there were 20 carriers, 13 fetuses with CF, and 20 healthy fetuses. Eight cases were healthy or carriers, who were free of the mutation detected in one parent, but had another unknown mutation, preventing confirmation of their genotype. Table 2 shows the genotypes of the 33 affected and carrier fetuses.
One sign suspicious of CF is meconium ileus. One of the fetuses homozygous for the p.F508del mutation, which usually has a severe clinical presentation, had meconium ileus. There was no family history of CF.
Five diagnoses were made using indirect study of markers XV2C/ Taq I and KM19/Pst I. One family was informative; it was possible to identify which marker alleles segregated with the disease, confirming the fetus as a carrier. Three cases were semi-informative for one marker or the other; in one of the parents it was possible to identify which marker alleles segregated with the disease, finding two affected or carrier fetuses and one healthy or carrier fetus. The final case, homozygous for both markers, was non-informative (Table 3). Direct diagnosis could not be made in these cases because they were not carrying any of the six mutations detectable in the laboratory.
Antenatal testing combining direct and indirect methods found four cases informative for the markers; in all cases, one parent was a carrier of the p.F508del mutation. Two fetuses were found to be carriers of p.F508del, and two were affected carriers of p.F508del and another unidentified mutation. The remaining six families were semi-informative for markers XV2C/Taq I and KM19/Pst I and one parent was a carrier of the p.F508del mutation. Of these, three fetuses were carriers of p.F508del, one was a carrier of an unknown mutation, one was affected (carrier of p.F508del and another unidentified mutation), and one fetus's status could not be confirmed (Table 4).
Conclusive diagnosis was possible in 72 cases (66.7% of those studied), of which 16 were affected, 27 carriers, 20 healthy, and 9 healthy or carrier fetuses.
Latin America is an extremely diverse region in population origin, culture and environment, CFTR gene mutation profiled across the region reflecting the heterogeneity of its inhabitants. Cuba's population today is the result of an admixture of contributions, mainly from Spanish and African ancestors.
Great genetic heterogeneity in populations with a wide spectrum of CFTR gene mutations makes it difficult to detect mutations, limiting molecular diagnosis of the disease, especially in patients with uncharacterized mutations. Therefore, in Cuba, a combination of direct and indirect testing methods is needed to increase the chances for antenatal and patient CT-carrier diagnosis. Similarly, in the Mexican population, Chávez reports that the most frequent combination of molecular strategies (such as targeted search for CFTR mutations) with marker linkage analysis, is very useful for carrier detection and antenatal diagnosis in families affected by CF.
Direct analysis for antenatal diagnosis of the CF molecular defect is only possible in families in which the specific mutation responsible for CF has been identified. In geographic regions such as Cuba, with great molecular heterogeneity and were the most frequent mutation (p.F508del) is less than 50%, direct antenatal diagnosis is only possible in roughly half the cases. In this study, diagnosis could be confirmed with direct mutation detection in 65.6% of couples studied, which was expected due to the frequency of the F508del mutation and mutations p.G542X, p.R1162X, p.R334W, p.R553X and c.3120+1G>A reported in prior studies.
Recently, other CFTR gene mutations have been identified in Cuban CF families, including I507del, G85E, 2184insA and G551D, also found in patients from other countries. This will make direct mutation diagnosis possible for these families, although the low frequency of these mutations will not enable substantial overall diagnostic improvement, such as is possible in northern European populations in which p.F508del alone is present in roughly 70%-90% of cases. Hence, indirect analysis will continue to be needed, in addition to direct mutation identification. Along with the RFLPs already in use, microsatellite markers will be used, which are more informative than those utilized in the present study. In fact, this method has been standardized and will be deployed in the future, increasing the number of couples that can be tested.
Although markers XV2C/Taq I and KM19/Pst I have been quite useful, they are not informative enough to sufficiently expand diagnostic possibilities, even though molecular diagnosis was possible in 40% of cases. One of the major limitations of indirect diagnosis in the families studied, in addition to lack of marker informativeness, was the death of the affected family member before molecular diagnosis could be done.
In Italy, a recent study of 181 couples at high risk for CF, testing failed to provide a diagnosis in a single case; of the remainder, 116 (64.4%) were diagnosed by mutation analysis; 40 (22.2%) required gene sequencing; 4 were tested for major rearrangements, and in 23, linkage analysis was done. In all, 42 of 180 (23.3%) fetuses were affected. The authors concluded that antenatal diagnosis of CF "should be performed in reference laboratories equipped for gene scanning and linkage analysis, with a multidisciplinary staff able to offer counseling to couples during all phases [of antenatal diagnosis]."
Despite limitations preventing confirmation of all antenatal diagnoses in Cuban families affected by CF, this study was possible because molecular tools for antenatal testing are now universally available through the public health system (not the case in all Latin American countries), providing more accurate genetic counseling and enabling over half the families studied to learn their offspring's status.
This facilitates more informed decisions by couples about the pregnancy, and if taken to term, about their child's future: when CF is diagnosed, the infant can receive special care from birth, for better prognosis and quality of life.
All CF-affected families in Cuba continue to be offered molecular diagnosis, and the scope is increasing with the ability to detect more informative new mutations and molecular markers.
Implementation of direct and indirect testing methods enabled antenatal molecular diagnosis in over half the fetuses studied, which is of great social value because of CF's burden on affected persons and their families.
1. El-Seedy A, Girodon E, Norez C, Pajaud J, Pasquet MC, de Becdelièvre A, et al. CFTR mutation combinations producing frequent complex alleles with different clinical and functional outcomes. Hum Mutat. 2012 Nov;33(11):1557-65.
2. Dickinson F, Batlle M, Razón R, Ramos L, Pérez M. Caracterización epidemiológica de pacientes pediátricos con fibrosis quística. Rev Cubana Pediatr [Internet]. 2005 Apr-Jun [cited 2012 Oct 6];77(2):[about 6 p.]. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75312005000200001&nrm=iso. Spanish.
3. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005 May 12;352(19):1992-2001.
4. Castellani C, Cuppens H, Macek M Jr, Cassiman JJ, Kerem E, Durie P, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros. 2008 May;7(3):179-96.
5. Casals T. Epidemiología y patogénesis. In: Manual de Fibrosis Quística. Barcelona: Sociedad científica de lucha contra la fibrosis quística; 2003. p. 13-9. Spanish.
6. Cystic fibrosis. A WHO/ICF(M)A meeting. Bull World Health Organ. 1985;63(1):1-10.
7. Collazo T. Estudio molecular de la fibrosis quística en Cuba [thesis]. [Havana]: University of Medical Sciences of Havana (CU); 2006. Spanish.
8. Razón R, Rodríguez F, Rojo M, González J, Abreu G, Pérez T, et al. La fibrosis quística en Cuba. Rev Cubana Pediatr. 2009;81(Suppl):S85-92. Spanish.
9. Kerem B, Rommens JM, Buchanan JA, Markiewicz DA, Cox TK, Chakravarti A, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989 Sep 8;245(4922):1073-80.
10. Cystic Fibrosis mutation database [Internet]. Toronto: Cystic Fibrosis Centre at the hospital for sick children in Toronto. c2010. CFMDB Statistics; [updated 2011 Apr 25; cited 2014 Jan 14]; [about 2 p.]. Available from: http://www.genet.sickkids.on.ca/StatisticsPage.html
11. Alonso MJ, Heine-Suñer D, Calvo M, Rosell J, Giménez J, Ramos MD, et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. Ann Hum Genet. 2007 Mar;71(Pt 2):194-201.
12. Ivady G, Madar L, Nagy B, Gonczi F, Ajzner E, Dzsudzsak E, et al. Distribution of CFTR mutations in Eastern Hungarians: relevance to genetic testing and to the introduction of newborn screening for cystic fibrosis. J Cyst Fibros. 2011 May;10(3):217-20.
13. Bieger AM, Marson FA, Bertuzzo CS. Prevalence of ΔF508 mutation in the cystic fibrosis transmembrane conductance regulator gene among cystic fibrosis patients from a Brazilian referral center. J Pediatr (Rio J). 2012 Nov-Dec;88(6):531-4.
14. Teruel BM, Rodríguez JJ, McKeigue P, Mesa TC, Fuentes E, Cepero AV, et al. Interactions between genetic admixture, ethnic identity, APOE genotype and dementia prevalence in an admixed Cuban sample; a cross-sectional population survey and nested case-control study. BMC Med Genet. 2011 Mar 24;12:43.
15. Collazo T, Bofill AM, Clark Y, Hernández Y, Gómez M, Rodríguez F, et al. Common mutations in Cuban cystic fibrosis patients. J Cyst Fibros. 2009 Jan;8(1):47-9.
16. Boúe A, Muller F, Nezelof C, Oury JF, Duchatel F, Dumez Y, et al. Prenatal Diagnosis in 200 pregnancies with ¼ risk of cystic fibrosis. Hum Gen. 1986 Nov;74(3):288-97.
17. Casals T, Nunes V, Lázaro C, Jiménez J, Girbau E, Volpini V, et al. Mutation and linkage disequilibrium analysis in genetic counselling of Spanish cystic fibrosis families. J Med Genet. 1991 Nov;28(11):771-6.
18. Baranov VS, Gorbunova VM, Ivaschenko TE, Shwed NYu, Osinovskaya NS, Kascheeva TK, et al. Five years' experience of prenatal diagnosis of cystic fibrosis in the former U.S.S.R. Prenat Diagn. 1992 Jul;12(7):575-86.
19. Miller SA. A simple salting out procedure for extracting DNA from human nucleoted cells. Nucleic Acids Res. 1988 Feb 11;16(3):1215.
20. Casals T, Nuñez V, Giménez J, Parra J, Estivill X. Diagnóstico prenatal de fibrosis quística en familias españolas utilizando marcadores del DNA: nuestra experiencia en 1987-1989. An Esp Pediatric. 1990 Apr;32(4):287-92. Spanish.
21. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, et al. Analysis any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989 Apr 11;17(7):2503-16.
22. Gasparini P, Borgo G, Mastella G, Bonizzato A, Dognini M, Pignatti PF. Nine cystic fibrosis patients homozygous for the CFTR nonsense mutation R1162X have mild or moderate lung disease. J Med Genet. 1992 Aug;29(8):558-62.
23. Cutting GR, Kash LM, Rosenstein BJ, Zielenski J, Tsui LC, Antonarakis SE, et al. A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein. Nature. 1990 Jul 26;346(6282):366-9.
24. Zielenski J, Rozmahel R, Bozon D, Kerem B, Grzelczak Z, Riordan JR, et al. Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics. 1991 May;10:214-28.
25. Pérez MM, Luna MC, Pivetta OH, Keyeux G. CFTR gene analysis in Latin American CF patients: heterogeneous origin and distribution of mutations across the continent. J Cyst Fibros. 2007 May;6(3):194-208.
26. Ustáriz CR, Morera LM, Hernández P, Estrada M, Bencomo A, García MA, et al. Origen y composición genética de la población cubana. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2011 [cited 2013 Jun 11];27(3):[about 4 p.]. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892011000300002&lng=es. Spanish.
27. Chávez M, García RJ, Vigueras RM, Orozco L. Diagnóstico prenatal en una familia con fibrosis quística: combinación de estrategias moleculares para un diagnóstico preciso. Rev Invest Clin. 2011 Jul-Aug;63(4):433-5. Spanish.
28. World Health Organization. The molecular genetic epidemiology of cystic fibrosis. Report of a joint meeting of WHO/ECFTN/ICF(M)A/ECFS. Geneva: World Health Organization; 2004.
29. Elce A, Boccia A, Cardillo G, Giordano S, Tomaiuolo R, Paolella G, et al. Three novel CFTR polymorphic repeats improve segregation analysis for cystic fibrosis. Clin Chem. 2009 Jul;55(7):1372-9.
30. González L, Collazo T, Clark Y, Gómez M, Reyes L. Caracterización del marcador microsatélite IVS17bTA y seis mutaciones del gen CFTR en 21 familias cubanas con fibrosis quística. Biotecnol Apl. 2013 Oct-Dec;30(4):262-6. Spanish.
31. Tomaiuolo R, Nardiello P, Martinelli P, Sacchetti L, Salvatore F, Castaldo G. Prenatal diagnosis of cystic fibrosis: an experience of 181 cases. Clin Chem Lab Med. 2013 Dec;51(12):2227-32.
Submitted: September 13, 2013
Approved for publication: July 29, 2014